Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15491228 | 0.80 | FFAR1 (0.38) | FFAR1FFAR4MAP2K1MAP2K2PYCR1 | |
| SCHEMBL29518342 | 0.80 | FFAR1 (0.45) | FFAR1FFAR4 | |
| SCHEMBL1162443 | 0.80 | FFAR1 (0.45) | FFAR1FFAR4 | |
| SCHEMBL24837945 | 0.80 | LOXL2 (0.38) | FFAR1FFAR4MAP2K1MAP2K2PYCR1 | |
| SCHEMBL8771783 | 0.77 | FFAR1 (0.43) | FFAR1FFAR4 | |
| SCHEMBL15132376 | 0.77 | FFAR1 (0.43) | FFAR1FFAR4 | |
| SCHEMBL5735234 | 0.76 | PYCR1 (0.35) | FFAR1PDK2PYCR1 | |
| SCHEMBL16286817 | 0.76 | PARP1 (0.36) | FFAR1MAP2K1MAP2K2PYCR1 | |
| SCHEMBL31371238 | 0.76 | IDO1 (0.59) | MAP2K1 | |
| SCHEMBL26016355 | 0.76 | NR3C1 (0.35) | FFAR1FFAR4MAP2K1MAP2K2PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102548975-A | Histone deacetylase inhibitors | PORTSMOUTH TECHNOLOGIES LLC | 2012-07-04 | — | — | CN | disclosed |
| EP-2451790-A1 | HISTONE DEACETYLASE INHIBITORS | Anthem Biosciences Private Limited (IN) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| WO-2011021209-A1 | HISTONE DEACETYLASE INHIBITORS | PORTSMOUTH TECHNOLOGIES LLC (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011021209-A1 | HISTONE DEACETYLASE INHIBITORS | PORTSMOUTH TECHNOLOGIES LLC (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC11 | FFAR1 4141/4885FFAR4 4465/4885PDK2 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.